NCT05735249View on ClinicalTrials.gov

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Oral ARN-75039 in Healthy Adult Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

94

Participants

Timeline

Start Date

January 9, 2023

Primary Completion Date

March 28, 2025

Study Completion Date

March 28, 2025

Conditions
Lassa Virus Infection
Interventions
DRUG

ARN-75039 oral capsules

SAD: Up to 5 single escalating doses MAD: Up to 3 escalating doses Food-effect: Selected single dose

DRUG

Placebo

Given at frequency and amounts matching ARN- 75039 dosing regimen

Trial Locations (1)

53095

Spaulding Clinical, LLC, West Bend

Sponsors
All Listed Sponsors
collaborator

The Defense Threat Reduction Agency (DTRA)

UNKNOWN

collaborator

United States Department of Defense

FED

collaborator

Battelle Memorial Institute

OTHER

lead

Arisan Therapeutics, Inc.

INDUSTRY

NCT05735249 - A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Oral ARN-75039 in Healthy Adult Subjects | Biotech Hunter | Biotech Hunter